CICLOPIROX SUMMARY
Ciclopirox Shampoo 1% contains the synthetic antifungal agent, ciclopirox.
Each gram (equivalent to 0.96 mL) of Ciclopirox Shampoo contains 10 mg ciclopirox in a shampoo base consisting of disodium laureth sulfosuccinate, laureth-2, purified water USP, sodium chloride USP and sodium laureth sulfate.
Ciclopirox Shampoo is a colorless to yellowish, translucent solution.
Ciclopirox Shampoo is indicated for the topical treatment of seborrheic dermatitis of the scalp in adults.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Ciclopirox
A randomized, double-blind study comparing the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. [2010.09] Our objective was to compare the efficacy of selenium sulfide shampoo 1% and ciclopirox shampoo 1% as adjunctive treatments for tinea capitis in children. Forty children aged 1-11 years with clinically diagnosed tinea capitis were randomized to receive selenium sulfide shampoo 1% or ciclopirox shampoo 1% twice a week as adjuncts to an 8-week course of ultramicronized griseofulvin dosed at 10-12 mg/kg/day...
Randomized study comparing the efficacy and tolerance of a lipohydroxy acid shampoo to a ciclopiroxolamine shampoo in the treatment of scalp seborrheic dermatitis. [2009.12] BACKGROUND: The success of a dandruff treatment depends not only on the ability of a shampoo to control dandruff, but also on patient compliance, which is closely linked to the cosmetic attributes of the product. AIM: The aim of this study was to compare efficacy, tolerance, and cosmetic properties of a LHA Shampoo [containing 0.1% lipohydroxy acid (LHA) and 1.3% salicylic acid] to a CPO shampoo [containing 1.5% ciclopiroxolamine (CPO), 3% salicylic acid, and 0.5% menthol] in subjects with seborrheic dermatitis (SD) of the scalp... CONCLUSION: In conclusion, these results demonstrated that the lipohydroxy acid shampoo evaluated in this study is a more convenient, efficient, safe, and well-tolerated cosmetic treatment for mild-to-moderate seborrheic dermatitis of the scalp than a ciclopiroxolamine shampoo.
An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis. [2009.07] BACKGROUND: A new 8% ciclopirox-medicated nail lacquer (P-3051), based on a new technology, revealed superior properties in terms of affinity to keratin, nail permeation, and ease of use. OBJECTIVE: This study aims to assess the efficacy and safety of P-3051 vs. the market 8% ciclopirox nail lacquer... CONCLUSION: Ciclopirox 8% hydrolacquer is more active than reference ciclopirox nail lacquer in the treatment of onychomycosis.
Double-Blind Clinical Trial for Evaluating the Effectiveness and Tolerability of Ageratina pichinchensis Extract on Patients with Mild to Moderate Onychomycosis. A Comparative Study with Ciclopirox. [2008.10] Aerial parts of AGERATINA PICHINCHENSIS have been used, in Mexican traditional medicine, as a remedy for the treatment of skin mycosis. Onychomycosis, also known as tinea of the nails or tinea unguium, constitutes an infection of the nails produced by dermatophytes.Statistical analysis demonstrated no differences between treatments.
An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis. [2007.11] BACKGROUND: Onychomycosis is a fungal infection of nails caused by dermatophytes, yeasts and molds. AIMS: To study the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in onychomycosis... CONCLUSION: Terbinafine pulse therapy is effective and safe alternative in treatment of onychomycosis due to dermatophytes; and combination therapy with topical ciclopirox or amorolfine do not show any significant difference in efficacy in comparison to monotherapy with oral terbinafine.
Clinical Trials Related to Ciclopirox
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy [Completed]
This is an open-label, single arm study. Approximately 3-30 patients will be enrolled.
Patients will receive Oral ciclopirox olamine (aqueous suspension), initial starting dose of
5 mg/m2/day administered as a single dose daily for 5 days. Three patients will initially be
treated at each dose level in sequential cohorts. Dose escalation will continue for each
subsequent cohort based on toxicity and plasma drug concentrations observed during the
previous cohort. Dose escalation will continue until establishment of the maximum tolerated
dose (MTD) has been met.
Patients who have demonstrated response to treatment, up to 6 total cycles of treatment may
be administered. If additional cycles are warranted, ciclopirox olamine will be given at
the same dose and frequency as the patient initially received.
Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis [Completed]
The objectives of this study were to demonstrate comparable safety and efficacy of
Ciclopirox Olamine Cream (Test Product) and Ciclopirox Cream 0. 77% (Reference Product) in
the treatment of subjects with tinea pedis, and to show the superiority of the active
treatments over that of the vehicle.
Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children [Terminated]
Ciclopirox olamine (CiclochemŪ) is a pyridone broad spectrum antifungal drug which has
shown activity on dermatophytes, yeasts, moulds, actinomycetes and some bacteria. Its
mechanism of action is based on a fungicidal activity by inhibiting the cellular captation
of essential substances needed for the metabolism and growth of the fungi. On the other
hand, this drug binds irreversibly with cell structures as mitochondria, ribosomes,
microsomes and cell wall. After dermal application, Ciclopirox olamine undergoes skin
penetration, being only absorbed a 1,5% of the applied dose. Clinical efficacy has been
studied in patients above 10 years with superficial dermatomycoses (dermatophytoses,
candidiasis and pityriasis versicolor) and the percentage of clinical healing ranged from
77% to 91% after 2-4 weeks of twice a day topical application. In all the studies, the
safety profile has been very good, showing only a very low rate of adverse events of mild to
moderate intensity. There are very few previous available data on the application of this
compound in children under 10 years of age. A single study had been performed with a
solution formulation in patients from 6 to 29 months with diaper candidiasis, showing good
efficacy and tolerability in these patients. The present study aims to show the safety and
tolerability of ciclopirox olamine in a cream formulation in patients from 3 months to 10
years with dermatomycoses.
Safety and Equivalence of a Generic Ciclopirox Olamine Topical Suspension Compared to the Reference Ciclopirox Topical Suspension 0.77% for the Treatment of Tinea Pedis [Completed]
The objectives of this study were to demonstrate comparable safety and efficacy of
Ciclopirox Olamine Topical Suspension (Test Product) and Ciclopirox Topical Suspension 0. 77%
(Reference Product) in the treatment of subjects with tinea pedis, and to show the
superiority of the active treatments over that of the vehicle.
Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis [Recruiting]
The purpose of the study is to evaluate and compare the efficacy of the sequential
association RV4104A ointment followed by ciclopiroxolamine 1% cream and ciclopirox 8%
film-forming solution versus amorolfine 5% nail lacquer alone in the treatment of patients
with dermatophytic onychomycosis (toenail) without matrix involvement.
|
|
Page last updated: 2011-12-09
|